NCT05990920View on ClinicalTrials.gov

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Pathologically Confirmed Cancer Refractory to Conventional TherapyRefractory CancerMetastatic CancerRecurrent CancerSolid Tumor, AdultSolid TumorAdvanced CancerAdvanced Solid Tumor
Interventions
BIOLOGICAL

SNK02

SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.

Trial Locations (2)

90025

Angeles Clinic and Research Institute, Los Angeles

90403

Sarcoma Oncology Center, Santa Monica

Sponsors
All Listed Sponsors
lead

NKGen Biotech, Inc.

INDUSTRY

NCT05990920 - Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | Biotech Hunter | Biotech Hunter